SEC
AKRO

Seven Eight Capital’s Akero Therapeutics AKRO Stock Holding History

Seven Eight Capital’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-40,384
Closed -$1.02M – 676
2024
Q1 		$1.02M Sell
40,384
-22,080
-35% -$530K 0.11% 297
2023
Q4 		$1.46M Buy
+62,464
New +$1.23M 0.17% 186

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Seven Eight Capital's AKRO Position: Q2 2024 in Review

Seven Eight Capital sold out of Akero Therapeutics (AKRO) in Q2 2024, closing a stake of 40,384 shares — an estimated $1.02M sold.

Seven Eight Capital first reported a position in AKRO in Q4 2023 and held it in 2 quarters. The position peaked at $1.46M in Q4 2023. 153 funds tracked by Wall St. Rank hold AKRO as of Q2 2024.

  • Seven Eight Capital reported no remaining Akero Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Seven Eight Capital sold 40,384 Akero Therapeutics shares in Q2 2024, an estimated $1.02M.
  • Seven Eight Capital first reported a position in Akero Therapeutics in Q4 2023 and held it in 2 quarters.
  • Seven Eight Capital's Akero Therapeutics position peaked at $1.46M in Q4 2023.
  • 153 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.